CoChat

TNIK inhibition abrogates colorectal cancer stemness

Open access

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Abstract

Canonical Wnt/β-catenin signalling is essential for maintaining intestinal stem cells, and its constitutive activation has been implicated in colorectal carcinogenesis. We and others have previously identified Traf2- and Nck-interacting kinase (TNIK) as an essential regulatory component of the T-cell factor-4 and β-catenin transcriptional complex. Consistent with this, Tnik -deficient mice are resistant to azoxymethane-induced colon tumorigenesis, and Tnik −/− / Apc min/+ mutant mice develop significantly fewer intestinal tumours. Here we report the first orally available small-molecule TNIK inhibitor, NCB-0846, having anti-Wnt activity. X-ray co-crystal structure analysis reveals that NCB-0846 binds to TNIK in an inactive conformation, and this binding mode seems to be essential for Wnt inhibition. NCB-0846 suppresses Wnt-driven intestinal tumorigenesis in Apc min/+ mice and the sphere- and tumour-forming activities of colorectal cancer cells. TNIK is required for the tumour-initiating function of colorectal cancer stem cells. Its inhibition is a promising therapeutic approach.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms12586

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Reduced tumorigenicity of Tnik-deficient mice. (a) Schematic representation of the Tnik allele and the targeting construct with the neomycin (neo) cassette driven by the phosphoglycerate kinase I (PGK) promotor as a positive selection marker and diphtheria toxin (DTA) as a negative selection marker. (b) Representative PCR-based genotyping (left) and relative Tnik gene expression (normalized to β-actin (Actb1)) in the brains of 10-week-old male wild-type (C57BL/6J-Tnik+/+), heterozygous mutant (Tnik+/−), and homozygous mutant (Tnik−/−) mice (right). Error bars represent s.e.m. (c) TCF/LEF transcriptional activity of MEFs derived from Tnik+/+, Tnik+/− and Tnik−/− embryos. MEFs were transfected with the superTOP-flash or superFOP-flash luciferase reporter in triplicate and treated with 30 ng ml−1 recombinant Wnt3a for 24 h or not. (d) Relative expression of Tnik and Wnt target genes (Axin2, Myc and Cd44) by MEFs derived from Tnik+/+ and Tnik−/− embryos. (e) Schedule of AOM treatment (top) and the mean number and maximum diameter of tumours developed in male Tnik+/+ (n=30), Tnik+/− (n=40) and Tnik−/− (n=18) mice at the age of 32 weeks (bottom). *P<0.05. (f) Macroscopic (so-called Swiss roll) view of whole small intestines of representative Apcmin/+/Tnik+/+, Apcmin/+/Tnik+/− and Apcmin/+/Tnik−/− mice. (g,h) Mean numbers and maximum diameters of tumours that developed in the small intestine and colon of 16-week-old male Apcmin/+/Tnik+/+ (n=30), Apcmin/+/Tnik+/− (n=19) and Apcmin/+/Tnik−/− (n=21) mice. ***P<0.001; **P<0.01; *P<0.05.
Figure 1 Reduced tumorigenicity of Tnik-deficient mice. (a) Schematic representation of the Tnik allele and the targeting construct with the neomycin (neo) cassette driven by the phosphoglycerate kinase I (PGK) promotor as a positive selection marker and diphtheria toxin (DTA) as a negative selection marker. (b) Representative PCR-based genotyping (left) and relative Tnik gene expression (normalized to β-actin (Actb1)) in the brains of 10-week-old male wild-type (C57BL/6J-Tnik+/+), heterozygous mutant (Tnik+/−), and homozygous mutant (Tnik−/−) mice (right). Error bars represent s.e.m. (c) TCF/LEF transcriptional activity of MEFs derived from Tnik+/+, Tnik+/− and Tnik−/− embryos. MEFs were transfected with the superTOP-flash or superFOP-flash luciferase reporter in triplicate and treated with 30 ng ml−1 recombinant Wnt3a for 24 h or not. (d) Relative expression of Tnik and Wnt target genes (Axin2, Myc and Cd44) by MEFs derived from Tnik+/+ and Tnik−/− embryos. (e) Schedule of AOM treatment (top) and the mean number and maximum diameter of tumours developed in male Tnik+/+ (n=30), Tnik+/− (n=40) and Tnik−/− (n=18) mice at the age of 32 weeks (bottom). *P<0.05. (f) Macroscopic (so-called Swiss roll) view of whole small intestines of representative Apcmin/+/Tnik+/+, Apcmin/+/Tnik+/− and Apcmin/+/Tnik−/− mice. (g,h) Mean numbers and maximum diameters of tumours that developed in the small intestine and colon of 16-week-old male Apcmin/+/Tnik+/+ (n=30), Apcmin/+/Tnik+/− (n=19) and Apcmin/+/Tnik−/− (n=21) mice. ***P<0.001; **P<0.01; *P<0.05.CC BY · PubMed Central
Figure 2 Identification of a novel TNIK inhibitor. (a) Structure of NCB-0846 (left) and its diastereomer NCB-0970 having the opposite configuration at the terminal hydroxyl group (right). (b) Inhibition of TNIK enzyme activity by the indicated concentration of NCB-0846 or NCB-0970. (c) Inhibitory profiles of NCB-0846 and NCB-0970 across the human kinome. The degree of inhibition is presented schematically by the size of the circles. (d) Inhibition of TCF4 phosphorylation by NCB-0846. The recombinant human TCF4 protein was incubated with the recombinant human TNIK protein in the presence of the indicated concentration of NCB-0846 or NCB-0970 and analysed by immunoblotting. (e) Inhibition of TNIK auto-phosphorylation by NCB-0846. HCT116 cells were cultured in the presence of DMSO (vehicle), 1 μM NCB-0846, or 1 μM NCB-0970 for 4 or 24 h and then analysed by immunoblotting with anti-phosphorylated TNIK, anti-TNIK, and anti-γ-tubulin (loading control) antibodies. (f) Suppression of TCF/LEF transcriptional activity by NCB-0846. HEK293 cells were transfected with pGL4.49[luc2P/TCF-LEF-RE/Hygro] and then treated with the indicated concentration of NCB-0846 or NCB-0970 for 24 h. The cells were then incubated with or without recombinant Wnt3a (10 ng ml−1) for 5 h before measurement of luciferase activity. Data are represented as ratios relative to the DMSO control (set at 100%)±s.e.m. (g) HCT116 (left) and DLD-1 (right) cells were transfected with one of the luciferase reporter plasmids (SuperTOP-flash or SuperFOP-flash) and then treated with 20 mM LiCl and the indicated concentration of NCB-0846 or NCB-0970 for 24 h. Data are presented as the ratios of SuperTOP-flash to SuperFOP-flash (TOP/FOP ratio). Error bars represent s.d. (h) HCT116 cells were treated with DMSO (control) or the indicated concentration of NCB-0846. Twenty-four hours later, the expression levels of the TNIK, AXIN2, CCND1 and MYC genes (normalized to ACTB) were quantified in triplicate by RT–PCR. The values of cells treated with DMSO were set to one. Error bars represent s.d. (i) HCT116 and DLD-1 cells were treated with DMSO (vehicle) or the indicated concentration of NCB-0846 or NCB-0970 for 48 h. The expression of TNIK, AXIN2, c-MYC, LRP6, LRP5 and β-actin (loading control) proteins was analysed by immunoblotting.
Figure 2 Identification of a novel TNIK inhibitor. (a) Structure of NCB-0846 (left) and its diastereomer NCB-0970 having the opposite configuration at the terminal hydroxyl group (right). (b) Inhibition of TNIK enzyme activity by the indicated concentration of NCB-0846 or NCB-0970. (c) Inhibitory profiles of NCB-0846 and NCB-0970 across the human kinome. The degree of inhibition is presented schematically by the size of the circles. (d) Inhibition of TCF4 phosphorylation by NCB-0846. The recombinant human TCF4 protein was incubated with the recombinant human TNIK protein in the presence of the indicated concentration of NCB-0846 or NCB-0970 and analysed by immunoblotting. (e) Inhibition of TNIK auto-phosphorylation by NCB-0846. HCT116 cells were cultured in the presence of DMSO (vehicle), 1 μM NCB-0846, or 1 μM NCB-0970 for 4 or 24 h and then analysed by immunoblotting with anti-phosphorylated TNIK, anti-TNIK, and anti-γ-tubulin (loading control) antibodies. (f) Suppression of TCF/LEF transcriptional activity by NCB-0846. HEK293 cells were transfected with pGL4.49[luc2P/TCF-LEF-RE/Hygro] and then treated with the indicated concentration of NCB-0846 or NCB-0970 for 24 h. The cells were then incubated with or without recombinant Wnt3a (10 ng ml−1) for 5 h before measurement of luciferase activity. Data are represented as ratios relative to the DMSO control (set at 100%)±s.e.m. (g) HCT116 (left) and DLD-1 (right) cells were transfected with one of the luciferase reporter plasmids (SuperTOP-flash or SuperFOP-flash) and then treated with 20 mM LiCl and the indicated concentration of NCB-0846 or NCB-0970 for 24 h. Data are presented as the ratios of SuperTOP-flash to SuperFOP-flash (TOP/FOP ratio). Error bars represent s.d. (h) HCT116 cells were treated with DMSO (control) or the indicated concentration of NCB-0846. Twenty-four hours later, the expression levels of the TNIK, AXIN2, CCND1 and MYC genes (normalized to ACTB) were quantified in triplicate by RT–PCR. The values of cells treated with DMSO were set to one. Error bars represent s.d. (i) HCT116 and DLD-1 cells were treated with DMSO (vehicle) or the indicated concentration of NCB-0846 or NCB-0970 for 48 h. The expression of TNIK, AXIN2, c-MYC, LRP6, LRP5 and β-actin (loading control) proteins was analysed by immunoblotting.CC BY · PubMed Central
Figure 3 NCB-0846 inhibits cancer cell growth in vitro and in vivo. (a) ATP production of HCT116 cells cultured with escalating doses of NCB-0846 or NCB-0970 for 72 h. IC50 values were obtained by fitting a four-parameter dose–response curve to normalized data using GraphPad Prism software. Data represent the mean of six replicates. (b) Inhibition of colony formation by HCT116 cells in soft agar. Cells were embedded in top agar, covered by media containing DMSO, NCB-0846 (1 μM) or NCB-0970 (1 μM), and cultured for 14 days. (c) HCT116 cells were inoculated into the subcutaneous tissues of 9-week-old female BALB/c-nu/nu mice. When the volume of the xenografts reached ∼80 mm3, the mice were administered daily with 0 (vehicle alone, n=9), 40 (n=9) or 80 mg kg−1 (n=9) BID (bis in die) NCB-0846. **P<0.01, ***P<0.001 (Dunnett's multiple comparison test). Error bars represent s.e.m. (d) Pharmacodynamics analysis. Mice carrying HCT116 xenografts of ∼650 mm3 received a single oral dose of 0 (distilled water, vehicle control, n=4), 90 (n=4) or 150 mg kg−1 (n=4) NCB-0846 HCl (hydrochloride salt of NCB-0846). The tumours were excised, and the expression of AXIN2, MYC and CCND1 was quantified by RT–PCR and normalized to ACTB. *P<0.05, **P<0.01 (Student's t test). (e) HCT116 cells were untreated (0 h) or treated with DMSO (control), NCB-0846 (3 μM) or NCB-0970 (3 μM) for 24 or 48 h. The percentage of cells in each cell cycle fraction was determined by flow cytometry. (f) HCT116 cells were treated with DMSO (control), NCB-0846 (1 μM) or NCB-0970 (1 μM) for 24 or 48 h. The expression of PARP-1 and γ-tubulin (loading control) was determined by immunoblotting. (g) Effects of NCB-0846 HCl on tumorigenicity in the small intestine and colon of Apcmin/+ mice. NCB-0846 HCl or water (VEH, vehicle) was orally administered BID for 35 days (10–15 weeks after birth). Data represent mean±s.e.m of 11–13 mice (Vehicle, n=12; 22.5 mg kg−1, n=11; 45 mg kg−1, n=13; 90 mg kg−1, n=13). ***P<0.001, **P<0.01 and *P<0.05 (Dunnett's test) relative to the vehicle-treated group.
Figure 3 NCB-0846 inhibits cancer cell growth in vitro and in vivo. (a) ATP production of HCT116 cells cultured with escalating doses of NCB-0846 or NCB-0970 for 72 h. IC50 values were obtained by fitting a four-parameter dose–response curve to normalized data using GraphPad Prism software. Data represent the mean of six replicates. (b) Inhibition of colony formation by HCT116 cells in soft agar. Cells were embedded in top agar, covered by media containing DMSO, NCB-0846 (1 μM) or NCB-0970 (1 μM), and cultured for 14 days. (c) HCT116 cells were inoculated into the subcutaneous tissues of 9-week-old female BALB/c-nu/nu mice. When the volume of the xenografts reached ∼80 mm3, the mice were administered daily with 0 (vehicle alone, n=9), 40 (n=9) or 80 mg kg−1 (n=9) BID (bis in die) NCB-0846. **P<0.01, ***P<0.001 (Dunnett's multiple comparison test). Error bars represent s.e.m. (d) Pharmacodynamics analysis. Mice carrying HCT116 xenografts of ∼650 mm3 received a single oral dose of 0 (distilled water, vehicle control, n=4), 90 (n=4) or 150 mg kg−1 (n=4) NCB-0846 HCl (hydrochloride salt of NCB-0846). The tumours were excised, and the expression of AXIN2, MYC and CCND1 was quantified by RT–PCR and normalized to ACTB. *P<0.05, **P<0.01 (Student's t test). (e) HCT116 cells were untreated (0 h) or treated with DMSO (control), NCB-0846 (3 μM) or NCB-0970 (3 μM) for 24 or 48 h. The percentage of cells in each cell cycle fraction was determined by flow cytometry. (f) HCT116 cells were treated with DMSO (control), NCB-0846 (1 μM) or NCB-0970 (1 μM) for 24 or 48 h. The expression of PARP-1 and γ-tubulin (loading control) was determined by immunoblotting. (g) Effects of NCB-0846 HCl on tumorigenicity in the small intestine and colon of Apcmin/+ mice. NCB-0846 HCl or water (VEH, vehicle) was orally administered BID for 35 days (10–15 weeks after birth). Data represent mean±s.e.m of 11–13 mice (Vehicle, n=12; 22.5 mg kg−1, n=11; 45 mg kg−1, n=13; 90 mg kg−1, n=13). ***P<0.001, **P<0.01 and *P<0.05 (Dunnett's test) relative to the vehicle-treated group.CC BY · PubMed Central
Figure 4 Structural basis of TNIK inhibition. (a) The crystal structures of NCB-0846-bound and Compound 9-bound TNIK-KDs (blue and green). NCB-0846 (yellow) and Compound 9 (magenta) are shown by sticks. The hydrophobic R-spine residues are shown by sticks with surface representations (white and red). (b) Superimpositions of apo TNIK-KD (grey, left panel) or Compound 9-bound TNIK-KD (green, right panel) onto NCB-0846-bound TNIK-KD (blue). (c) NCB-0846 in the ATP-binding site of TNIK-KD. Hydrogen bonds are indicated by dashed lines. (d) Comparison of Compound 9 (magenta) and NCB-0846 (yellow) binding sites. (e) Differences in αC-helix position and DFG motif between NCB-0846-bound TNIK-KD (blue) and Compound 9-bound TNIK-KD (green). In Compound 9-bound TNIK-KD, the Lys54/Glu69 salt bridge (red dashed line, 2.7 Å) and the hydrogen bonding network (black dashed lines) mediated by water molecules (cyan balls) are indicated. (f) Superimpositions of Compound 9-bound TNIK-KD (green) onto the active state of PKA (wheat) bound to ATP (orange sticks).
Figure 4 Structural basis of TNIK inhibition. (a) The crystal structures of NCB-0846-bound and Compound 9-bound TNIK-KDs (blue and green). NCB-0846 (yellow) and Compound 9 (magenta) are shown by sticks. The hydrophobic R-spine residues are shown by sticks with surface representations (white and red). (b) Superimpositions of apo TNIK-KD (grey, left panel) or Compound 9-bound TNIK-KD (green, right panel) onto NCB-0846-bound TNIK-KD (blue). (c) NCB-0846 in the ATP-binding site of TNIK-KD. Hydrogen bonds are indicated by dashed lines. (d) Comparison of Compound 9 (magenta) and NCB-0846 (yellow) binding sites. (e) Differences in αC-helix position and DFG motif between NCB-0846-bound TNIK-KD (blue) and Compound 9-bound TNIK-KD (green). In Compound 9-bound TNIK-KD, the Lys54/Glu69 salt bridge (red dashed line, 2.7 Å) and the hydrogen bonding network (black dashed lines) mediated by water molecules (cyan balls) are indicated. (f) Superimpositions of Compound 9-bound TNIK-KD (green) onto the active state of PKA (wheat) bound to ATP (orange sticks).CC BY · PubMed Central
Figure 5 TNIK inhibition abrogates colorectal cancer stemness. (a) HCT116 cells were treated with DMSO (vehicle), NCB-0846 (3 μM), or NCB-0970 (3 μM) for 48 or 72 h. The expression of the indicated proteins was analyzed by immunoblotting. (b) HCT116 cells were treated with DMSO (vehicle), NCB-0846 (1 μM) or NCB-0970 (1 μM) for 48 or 72 h. The population of cells with ALDEFLUOR intake in the presence (negative control) and absence of N,N- DEAB was determined by flow cytometry. Gates were set according to the highest intake of ALDEFLUOR by cells in the DEAB control. Abbreviation: SSC, side scatter. (c) Reduction in the frequency of sphere-forming cells by NCB-0846. HCT116 and DLD-1 cells were treated with DMSO, or with the indicated concentration of NCB-0846 or NCB-0970, for 3 or 4 days. Viable cells were distributed into 96-well U-bottomed culture clusters at a density of 1, 10 or 100 cells per well and cultured for 10 days. The frequency of sphere-forming cells was computed using ELDA software (***P<0.001 relative to DMSO). (d) Reduction of colorectal cancer cell tumour formation by NCB-0846. HCT116 and DLD-1 cells were treated with DMSO (control), NCB-0846 (1 μM) or NCB-0970 (1 μM) for 96 h. Viable cells were injected into the subcutaneous tissues of 6-week-old male NOD/ShiJic-scid mice at a density of 10, 100, 1,000 or 1 × 104 cells per mouse. Thirty-five (HCT116) and 40 (DLD-1) days later, the number of mice that had developed tumours was counted. The frequency of tumour-forming cells was calculated using ELDA software (***P<0.001 relative to DMSO). CIC, cancer-initiating cell.
Figure 5 TNIK inhibition abrogates colorectal cancer stemness. (a) HCT116 cells were treated with DMSO (vehicle), NCB-0846 (3 μM), or NCB-0970 (3 μM) for 48 or 72 h. The expression of the indicated proteins was analyzed by immunoblotting. (b) HCT116 cells were treated with DMSO (vehicle), NCB-0846 (1 μM) or NCB-0970 (1 μM) for 48 or 72 h. The population of cells with ALDEFLUOR intake in the presence (negative control) and absence of N,N- DEAB was determined by flow cytometry. Gates were set according to the highest intake of ALDEFLUOR by cells in the DEAB control. Abbreviation: SSC, side scatter. (c) Reduction in the frequency of sphere-forming cells by NCB-0846. HCT116 and DLD-1 cells were treated with DMSO, or with the indicated concentration of NCB-0846 or NCB-0970, for 3 or 4 days. Viable cells were distributed into 96-well U-bottomed culture clusters at a density of 1, 10 or 100 cells per well and cultured for 10 days. The frequency of sphere-forming cells was computed using ELDA software (***P<0.001 relative to DMSO). (d) Reduction of colorectal cancer cell tumour formation by NCB-0846. HCT116 and DLD-1 cells were treated with DMSO (control), NCB-0846 (1 μM) or NCB-0970 (1 μM) for 96 h. Viable cells were injected into the subcutaneous tissues of 6-week-old male NOD/ShiJic-scid mice at a density of 10, 100, 1,000 or 1 × 104 cells per mouse. Thirty-five (HCT116) and 40 (DLD-1) days later, the number of mice that had developed tumours was counted. The frequency of tumour-forming cells was calculated using ELDA software (***P<0.001 relative to DMSO). CIC, cancer-initiating cell.CC BY · PubMed Central
Figure 6 Patient-derived cancer-initiating cells. (a) Phase-contrast (left) and fluorescence (right) microscopy of a spheroid clone (named #6 Cl. 2) expressing Wnt-responsive promoter-driven green fluorescent protein (GFP). (b) GFP expression of a spheroid clone #6 Cl. 2 (right) and a control clone (#6 Cont.) (left) determined by flow cytometry. (c) Dose-dependent reduction of cells expressing Wnt-driven GFP in a spheroid clone #6 Cl. 2 by NCB-0846. (d) ATP production of spheroids #6 and #19 cultured for 3 days in the presence of the indicated concentration of NCB-0846 or NCB-0970. NA, not available (>3 μM). (e) Spheroid #6 was treated with DMSO (vehicle), NCB-0846 (1 μM), or NCB-0970 (1 μM) for 96 h. The population of cells expressing CD133, CD44, CD24, CD166, CD29 and EpCAM was determined by dual-color flow cytometry. APC, allophycocyanin; PE, phycoerythrin. (f) NOD/ShiJic-scid mice engrafted with patient-derived colon cancer spheroid #6 (1 × 104 cells) (top) or #19 (1 × 105 cells) (bottom) were orally administered NCB-0846 HCl (0, 50, or 100 mg kg−1, BID). *P<0.05, ***P<0.001 (Dunnett's test). Error bars represent s.e.m. (g) Excised tumours from mice engrafted with spheroid #6 and treated as described in f were analysed immunohistochemically with anti-Ki67 and anit-CD44v9 antibodies. Scale bar, 100 μm.
Figure 6 Patient-derived cancer-initiating cells. (a) Phase-contrast (left) and fluorescence (right) microscopy of a spheroid clone (named #6 Cl. 2) expressing Wnt-responsive promoter-driven green fluorescent protein (GFP). (b) GFP expression of a spheroid clone #6 Cl. 2 (right) and a control clone (#6 Cont.) (left) determined by flow cytometry. (c) Dose-dependent reduction of cells expressing Wnt-driven GFP in a spheroid clone #6 Cl. 2 by NCB-0846. (d) ATP production of spheroids #6 and #19 cultured for 3 days in the presence of the indicated concentration of NCB-0846 or NCB-0970. NA, not available (>3 μM). (e) Spheroid #6 was treated with DMSO (vehicle), NCB-0846 (1 μM), or NCB-0970 (1 μM) for 96 h. The population of cells expressing CD133, CD44, CD24, CD166, CD29 and EpCAM was determined by dual-color flow cytometry. APC, allophycocyanin; PE, phycoerythrin. (f) NOD/ShiJic-scid mice engrafted with patient-derived colon cancer spheroid #6 (1 × 104 cells) (top) or #19 (1 × 105 cells) (bottom) were orally administered NCB-0846 HCl (0, 50, or 100 mg kg−1, BID). *P<0.05, ***P<0.001 (Dunnett's test). Error bars represent s.e.m. (g) Excised tumours from mice engrafted with spheroid #6 and treated as described in f were analysed immunohistochemically with anti-Ki67 and anit-CD44v9 antibodies. Scale bar, 100 μm.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Cited by

See all 185

Metadata

Authors
Masuda, M., Uno, Y., Ohbayashi, N., Ohata, H., Mimata, A., Kukimoto-Niino, M., Moriyama, H., Kashimoto, S., Inoue, T., Goto, N., Okamoto, K., Shirouzu, M., Sawa, M., & Yamada, T.
Affiliations
  • National Cancer Centre Japan (JP)
  • Carna Biosciences (Japan) (JP)
  • RIKEN (JP)
  • National Cancer Center Research Institute (JP)
Corresponding author
Yamada, Tesshi
Venue
Nature Communications
Published
2016-08-26
Volume
7
Issue
1
Pages
12586-12586
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2506489222
Cited by
168
References
65
Citations by year
2026: 11 · 2025: 18 · 2024: 23 · 2023: 17 · 2022: 32 · 2021: 24 · 2020: 16 · 2019: 6 · 2018: 10 · 2017: 9 · 2016: 2
FWCI
4.68
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Institutional Repositories DataBase (IRDB) (submittedVersion)
Funders
  • Japan Agency for Medical Research and Development
  • National Institute of Biomedical Innovation
  • Japan Society for the Promotion of Science (26293073, 15K14390)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
TNIK, colorectal cancer stem cells, Wnt/β-catenin signaling, small-molecule kinase inhibitors, intestinal tumorigenesis, ApcMin/+ mice, T-cell factor 4, co-crystal structure, colorectal cancer treatment
MeSH terms
Germinal Center Kinases, Administration, Oral, Aged, Animals, Azoxymethane, Cell Transformation, Neoplastic, Female, Humans, Imidazoles, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Nude, Middle Aged, Mutation, Protein Binding, Quinazolines, Recombinant Proteins, Neoplastic Stem Cells, Colorectal Neoplasms, Protein Serine-Threonine Kinases, Mice, Knockout, Crystallography, X-Ray, Xenograft Model Antitumor Assays, Adenomatous Polyposis Coli Protein, Ubiquitin-Protein Ligases, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Wnt Proteins, beta Catenin, Mice, Wnt Signaling Pathway, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TNIK inhibition abrogates colorectal cancer stemness. https://app.cochat.ai/papers/10.1038/ncomms12586
The paper
Masuda, M., Uno, Y., Ohbayashi, N., Ohata, H., Mimata, A., Kukimoto-Niino, M., Moriyama, H., Kashimoto, S., Inoue, T., Goto, N., Okamoto, K., Shirouzu, M., Sawa, M., & Yamada, T. (2016). TNIK inhibition abrogates colorectal cancer stemness. Nature Communications. https://doi.org/10.1038/ncomms12586

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.